
A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.

A phase 1/2 trial shows saruparib combined with ARPI offers high response rates and manageable safety in metastatic prostate cancer patients.


Anbenitamab plus chemotherapy significantly improves survival rates in HER2-positive gastric cancer patients, offering a promising new treatment option.

Durvalumab combined with FLOT chemotherapy significantly enhances overall survival in resectable gastric adenocarcinoma, establishing a new standard of care.

New research suggests using mpMRI for bladder cancer staging improves survival rates, potentially changing standard diagnostic practices.

Zongertinib shows promising results as a first-line treatment for advanced HER2-mutant NSCLC, achieving high response rates and significant clinical benefits.

A new treatment regimen for metastatic prostate cancer shows significant reductions in severe adverse events, offering a promising alternative for patients.

Cevostamab delivered feasible and well-tolerated antitumor activities post CAR T-cell therapy in patients with heavily pretreated multiple myeloma.

In an interview with Targeted Oncology, Justin Watts, MD spoke about the long-term durability findings with olutasidenib and the next steps for IDH inhibitors in AML.

Atezolizumab shows no significant benefit over BCG alone in treating high-risk non-muscle invasive bladder cancer, according to the ALBAN trial results.

The triplet regimen of berdomide, daratumumab (Darzalex), and dexamethasone has led to deepening responses in newly diagnosed, transplant-ineligible patients with multiple myeloma.

A new study reveals serplulimab significantly improves event-free survival in gastric cancer, offering a promising alternative to traditional chemotherapy.

FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data and innovative technology.

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin.

Medicaid expansion significantly improves long-term cancer survival rates, especially for vulnerable populations, highlighting the need for broader adoption across states.

FDA designates MNV-201 as an orphan drug for myelodysplastic syndrome, highlighting its innovative approach to mitochondrial dysfunction treatment.

A new study shows mRNA-4359 combined with pembrolizumab offers promising results for melanoma patients resistant to prior therapies.

Tagraxofusp shows manageable safety but limited efficacy in chronic myelomonocytic leukemia (CMML), with ongoing studies exploring combination therapies for better outcomes.

Acalabrutinib shows high efficacy and safety for treating chronic lymphocytic leukemia in older, frail patients, improving frailty scores significantly.

Tucatinib enhances progression-free survival (PFS) in HER2+ metastatic breast cancer, showcasing promising results in a pivotal phase 3 trial.

T-cell engagers are a welcome addition to the oncologist's armamentarium, but managing associated adverse events is important to obtain the drugs' optimal benefit. Here are some suggestions.

Discover the most anticipated abstracts on gastrointestinal cancers at the 2025 ESMO Congress, featuring groundbreaking studies and innovative treatments.

The FDA fast-tracks NG-350A, an innovative immunotherapy for advanced rectal cancer, aiming to enhance treatment options and patient outcomes.

The FDA's new guidance reshapes oncology trial designs, emphasizing overall survival as a key endpoint to enhance drug development and patient safety.

Xevinapant fails to enhance event-free survival (EFS) in head and neck cancer patients, revealing safety concerns and detrimental effects in treatment outcomes.

Physician shortages drive urgent discussions on compensation, burnout, and patient access, highlighting the need for transparency and cultural alignment in healthcare.

The FDA designates ficerafusp alfa as a breakthrough therapy for treating HPV-negative head and neck cancer, enhancing patient outcomes and options.

Sonrotoclax receives FDA breakthrough designation, promising new hope for patients with relapsed mantle cell lymphoma after standard treatments fail.

New findings reveal that combining niraparib with abiraterone significantly extends progression-free survival in patients with HRR-altered metastatic prostate cancer.

New dosimetry data highlights the safety and efficacy of ITM-11 for treating patients with gastroenteropancreatic neuroendocrine tumors, promising improved outcomes.